Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Pulmonx (NASDAQ: LUNG), a global leader in minimally invasive treatments for lung disease, has announced it will release its fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. The company will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both the live and archived webcast of the event through the company's investor relations website.
Pulmonx (NASDAQ: LUNG), leader globale nei trattamenti minimamente invasivi per le malattie polmonari, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'anno intero 2024 dopo la chiusura del mercato mercoledì 19 febbraio 2025. L'azienda terrà una conferenza telefonica per discutere i risultati alle 13:30 PT / 16:30 ET dello stesso giorno. Gli investitori possono accedere sia alla diretta che alla registrazione dell'evento attraverso il sito web delle relazioni con gli investitori dell'azienda.
Pulmonx (NASDAQ: LUNG), líder mundial en tratamientos mínimamente invasivos para enfermedades pulmonares, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado el miércoles 19 de febrero de 2025. La compañía llevará a cabo una llamada de conferencia para discutir los resultados a la 1:30 p.m. PT / 4:30 p.m. ET el mismo día. Los inversores pueden acceder tanto a la transmisión en vivo como a la grabación del evento a través del sitio web de relaciones con inversores de la empresa.
Pulmonx (NASDAQ: LUNG)는 폐 질환을 위한 최소 침습 치료의 글로벌 리더로서, 2024년 4분기 및 전체 연도의 재무 결과 발표를 2025년 2월 19일 수요일 시장 마감 후에 진행할 것이라고 발표했습니다. 회사는 같은 날 오후 1시 30분 PT / 오후 4시 30분 ET에 결과에 대해 논의하는 컨퍼런스 콜을 개최할 예정입니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 이 이벤트의 실시간 및 아카이브 된 웹캐스트에 접근할 수 있습니다.
Pulmonx (NASDAQ: LUNG), un leader mondial dans les traitements mini-invasifs des maladies pulmonaires, a annoncé qu'il publiera ses résultats financiers du quatrième trimestre et de l'année entière 2024 après la clôture du marché le mercredi 19 février 2025. La société tiendra une conférence téléphonique pour discuter des résultats à 13h30 PT / 16h30 ET le même jour. Les investisseurs peuvent accéder à la diffusion en direct et à l'enregistrement de l'événement via le site Web des relations investisseurs de l'entreprise.
Pulmonx (NASDAQ: LUNG), ein weltweit führendes Unternehmen in der minimalinvasiven Behandlung von Lungenerkrankungen, hat bekannt gegeben, dass es seine Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 nach Börsenschluss am Mittwoch, den 19. Februar 2025, veröffentlichen wird. Das Unternehmen wird am gleichen Tag um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können sowohl auf das Live- als auch auf das archivierte Webcast-Event über die Investor-Relations-Website des Unternehmens zugreifen.
- None.
- None.
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Wednesday, February 19, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
When will Pulmonx (LUNG) release Q4 and full year 2024 earnings?
What time is Pulmonx (LUNG) Q4 2024 earnings call?
Where can I access Pulmonx (LUNG) Q4 2024 earnings webcast?
What period will Pulmonx's (LUNG) upcoming earnings report cover?
